NEUCHATEL, Switzerland--(BUSINESS WIRE)--Aug. 18, 2016--
Masimo
(NASDAQ: MASI) announced today the CE Marking of RAS-45, a single-use
adult and pediatric acoustic respiration sensor for rainbow Acoustic
Monitoring® (RAM™) of respiration rate (RRa®).
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20160818005451/en/
Masimo Root with rainbow Acoustic Monitoring (RAM) of Respiration Rate (RRa) with RAS-45 Sensor (Photo: Business Wire)
Continuous monitoring of respiration rate is especially important for
post-surgical patients receiving patient-controlled analgesia for pain
management. The Anesthesia Patient Safety Foundation (APSF) and The
Joint Commission recommend continuous oxygenation and ventilation
monitoring for all patients receiving opioid-based pain medications.1,2
RAM noninvasively and continuously measures respiration rate using an
innovative adhesive sensor with an integrated acoustic transducer, such
as Masimo’s RAS-125c and now RAS-45, that is applied to the patient’s
neck. Using acoustic signal processing that leverages Masimo’s
breakthrough Signal Extraction Technology (SET®), the
respiratory signal is separated and processed to display continuous
acoustic respiration rate (RRa). RRa has been shown to be accurate,
easy-to-use, and reliable, and to enhance patient compliance.3,4
RRa may facilitate earlier detection of respiratory compromise and
patient distress, offering a breakthrough in patient safety for
post-surgical patients and for procedures requiring conscious sedation.4
RAS-45 is designed to facilitate placement on and improve attachment to
the neck, but with a smaller adhesive profile than the RAS-125c. It is
flexible and uses a transparent adhesive. Like the RAS-125c, it operates
with Masimo MX technology boards to measure RRa and display the acoustic
respiration wave form. RAS-45 maintains the same performance parameters,
range, and accuracy specifications as RAS-125c. Both sensors are for
patients who weigh more than 10 kg.
Joe Kiani, Founder and CEO of Masimo, commented, “RAM harnesses the
power of our breakthrough signal processing technology, using Masimo SET®
and rainbow® technologies, and applies those achievements to
a respiratory measurement derived from the sound of breathing. Studies
have found that RAM RRa is more sensitive to detecting respiratory pause5
and yet easier for clinicians and patients to use.”3
@MasimoInnovates
| #Masimo
References
1 Stoelting, RK et al. APSF newsletter. 2011. www.apsf.org.
2 The Joint Commission Sentinel Event Alert. Issue 49, August 8, 2012. www.jointcomission.org.
3 Macknet MR et al. Anesthesiology. 2007;107:A84 (abstract).
4 Goudra BG et al. Open J Anesthesiol. 2013;3:74-79.
5 Ramsay MAE et al. Anesthesia-analgesia. 2013:117:1.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® is estimated
to be used on more than 100 million patients in leading hospitals and
other healthcare settings around the world. In 2005, Masimo introduced
rainbow® Pulse CO-Oximetry technology, allowing noninvasive
and continuous monitoring of blood constituents that previously could
only be measured invasively, including total hemoglobin (SpHb®),
oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability
Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to
SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo
introduced Root®, an intuitive patient monitoring and
connectivity platform with the Masimo Open Connect™ (MOC-9™) interface.
Masimo is also taking an active leadership role in mHealth with products
such as the Radius-7™ wearable patient monitor and the MightySat™
fingertip pulse oximeter. Additional information about Masimo and its
products may be found at www.masimo.com.
All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo RAM™, RRa®, and RAS-45. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique noninvasive
measurement technologies, including Masimo RAM, RRa, and RAS-45,
contribute to positive clinical outcomes and patient safety; risks
related to our belief that Masimo noninvasive medical breakthroughs
provide cost-effective solutions with comparable accuracy and unique
advantages, including: immediate and continuous results that enable
earlier treatment without causing invasive trauma in all patients and in
every clinical situation; as well as other factors discussed in the
"Risk Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160818005451/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com